Everett Laboratories, Inc. and Trigen Laboratories, Inc. Settle Patent Dispute

WEST ORANGE, N.J., Aug. 15, 2012 /PRNewswire/ -- Everett Laboratories, Inc. ("Everett") and Trigen Laboratories, Inc. ("Trigen") have entered into a confidential agreement settling all claims, including patent infringement claims brought by Everett against Trigen, involved in the lawsuit brought by Everett against Trigen in federal court in New Jersey.  Pursuant to the settlement and the terms of a Consent Judgment and Permanent Injunction agreed to by the parties and without any admission of liability, Trigen has ceased all manufacture, sales and distribution of its TL-Assure One and TL-Assure+DHA prenatal vitamin supplements and discontinued their National Drug Code numbers.  Everett continues to sell its Vitafol® One and Select-OB®+DHA prenatal vitamin supplements.  "We are very pleased with this agreement and are gratified to see our Vitafol® One and Select-OB®+DHA prenatal vitamin supplements retain their rightful place in the market.  We continue to have confidence in the strength of our patents and will vigorously defend our intellectual property," said Lucas Sigman, Chief Executive Officer of Everett Laboratories, Inc. 

SOURCE Everett Laboratories, Inc.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.